<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805411</url>
  </required_header>
  <id_info>
    <org_study_id>CM310AD002</org_study_id>
    <nct_id>NCT04805411</nct_id>
  </id_info>
  <brief_title>Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled Phase IIb Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keymed Biosciences Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keymed Biosciences Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double blind, placebo-controlled phase IIb study to&#xD;
      evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in moderate-severe AD&#xD;
      subjects. The study consists of 3 periods, a up-to-4-week Screening Period, a 16-week&#xD;
      randomized Treatment Period and a 8-week Safety Follow-up Period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be required to apply moisturizers after ICF signed and continue throughout the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EASI-75</measure>
    <time_frame>at Week 16</time_frame>
    <description>Proportion of subjects with EASI-75 (≥75 percent improvement from baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA) 0/1</measure>
    <time_frame>at week 16</time_frame>
    <description>Proportion of subjects with IGA 0 or 1 (on a 6-point scale, range from 0-5 point, higher scores mean a worse disease severity) and a reduction from baseline of ≥2 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of IGA from baseline of ≥ 2 points</measure>
    <time_frame>at week 16</time_frame>
    <description>Proportion of subjects with IGA 0 or 1 (on a 6-point scale, range from 0-5 point, higher scores mean a worse disease severity) and a reduction from baseline of ≥2 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Eczema Area and Severity Index (EASI)-90</measure>
    <time_frame>at week 16</time_frame>
    <description>Proportion of subjects with EASI-90 (≥90 percent improvement from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Eczema Area and Severity Index (EASI)-50</measure>
    <time_frame>at week 16</time_frame>
    <description>Proportion of subjects with EASI-50 (≥50 percent improvement from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Numerical Rating Scale (NRS)</measure>
    <time_frame>at week 16</time_frame>
    <description>Proportion of subjects with improvement (reduction) of pruritus NRS of ≥4 points from baseline. The range of NRS is from 0 (no itch)-10 (worst imaginable itch).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface Area (BSA)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in percent of BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in DLQI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Incidence of AE, abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>trough concentration and exposure of CM310</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Serum Thymus and activation regulated chemokine (TARC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Total IgE level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Detection of anti-drug antibody (ADA)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Moderate-to-severe Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>High-dose arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg for 1st dose, and then 300 mg for 2-8nd doses, every 2 weeks, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low-dose arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg for 1st dose, and then 150 mg for 2-8nd doses, every 2 weeks, SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for 1-8 doses, every 2 weeks, SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CM310</intervention_name>
    <description>IL-4Rα monoclonal antibody</description>
    <arm_group_label>High-dose arm</arm_group_label>
    <arm_group_label>low-dose arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as AD for at least 12 months before Screening, with below requirements:&#xD;
             1)EASI score ≥16 at Screening and Baseline; 2) IGA score ≥3 (0-5 points scale) at&#xD;
             Screening and Baseline; 3) ≥10% BSA of AD involvement at Screening and Baseline; 4)&#xD;
             Pruritus NRS average score ≥3 at Baseline.&#xD;
&#xD;
          -  Inadequate response to topical medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not enough washing-out period for previous therapy.&#xD;
&#xD;
          -  Concurrent disease/status which may potentially affect the efficacy/safety judgement.&#xD;
&#xD;
          -  Organ dysfunction.&#xD;
&#xD;
          -  pregnancy.&#xD;
&#xD;
          -  Other.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Traditional Chinese Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi Second Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital of Dermatology</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Skin Disease Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo Second Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

